International Journal of Clinical Case Reports 2024, Vol.14, No.5, 253-261 http://medscipublisher.com/index.php/ijccr 259 Consoli A., Formoso G., Baldassarre M.D., and Febo F., 2018, A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment, Expert Opinion on Drug Safety: 17: 293-302. https://doi.org/10.1080/14740338.2018.1428305 PMID: 29334278 DeFronzo R., 2017, Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor, Diabetes, 19: 1-10. https://doi.org/10.1111/dom.12982 PMID: 28432726 PMCID: PMC5643008 Díaz-Trastoy O., Villar-Taibo R., Sifontes-Dubón M., Mozo-Peñalver H., Bernabeu-Morón I., Cabezas-Agrícola J.M., Muñoz-Leira V., Peinó-García R., Martís-Sueiro A., García-López J.M., and Martínez-Olmos M.A., 2020, GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-life clinical practice, Clinical Therapeutics, 42(2): 1-12. https://doi.org/10.1016/j.clinthera.2019.12.012 PMID: 32005534 Edwards K., Li X., and Lingvay I., 2022, Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study, The Journal of Clinical Endocrinology and Metabolism, 108(4): 920-930. https://doi.org/10.1210/clinem/dgac618 PMID: 36268825 Guo M., Gu J., Li J., and Xu Y., 2019, 2300-PUB: the efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and meta-analysis, Diabetes, 67(2): 294-304. https://doi.org/10.2337/DB19-2300-PUB PMID: 31900793 Guo M., Gu J., Li J., and Xu Y., 2020, The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and meta-analysis, Endocrine, 67: 294-304. https://doi.org/10.1007/s12020-019-02175-6 PMID: 31900793 Jarosinski M., Chen Y., Varas N., Dhayalan B., and Chatterjee D., 2021, New horizons: next-generation insulin analogs: structural principles and clinical goals, The Journal of Clinical Endocrinology and Metabolism, 107(4):909-928. https://doi.org/10.1210/clinem/dgab849 PMID: 34850005 PMCID: PMC8947325 Kaku K., Watada H., Iwamoto Y., Utsunomiya K., Terauchi Y., Tobe K., Tanizawa Y., Araki E., Ueda M., Suganami H., and Watanabe D., 2014, Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus, Cardiovascular Diabetology, 13: 65-65. https://doi.org/10.1186/1475-2840-13-65. PMID: 24678906 PMCID: PMC4021346 Kim C.H., Hwang I., Ahn C.H., Yoon Y., and Cho G., 2021, Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus, International Journal of Cardiology, 364: 104-111. https://doi.org/10.21203/rs.3.rs-734897/v1 PMID: 35716949 Levina A., and Lay P.A., 2020, Metal-based anti-diabetic drugs: advances and challenges, Dalton Transactions, 40(44): 11675-11686. https://doi.org/10.1039/c1dt10380f PMID: 21750828 Linsley P., Greenbaum C., and Nepom G., 2021, Uncovering pathways to personalized therapies in type 1 diabetes, Diabetes, 70(4): 831-841. https://doi.org/10.2337/db20-1185 PMID: 33741606 PMCID: PMC7980192 Luo M.T., 2024, Unveiling the genetic heterogeneity of type 2 diabetes: from multi-ethnic studies to personalized medicine, Evidence, 14(1): 11-15. https://doi.org/10.5376/be.2024.14.0002 Palmer S.C., Tendal B., Mustafa R.A., Vandvik P.O., Li S., Hao Q., Tunnicliffe D., Ruospo M., Natale P., Saglimbene V., Nicolucci A., Johnson D.W., Tonelli M., Rossi M. C., Badve S.V., Cho Y., Nadeau-Fredette A.C., Burke M., Faruque L.I., Lloyd A., Ahmad N., Liu Y., Tiv S., Millard T., Gagliardi L., Kolanu N., Barmanray R.D., McMorrow R., Cortez A.K.R., White H., Chen X., Zhou X., Liu J., Rodríguez A.F., González-Colmenero A.D., Wang Y., Li L., Sutanto S., Solis R.C., González-Colmenero F.D., Rodriguez-Gutierrez R., Walsh M., Guyatt G., Strippoli G.F.M., and Strippoli G.F.M., 2021, Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomized controlled trials, The BMJ, 372: m4573. https://doi.org/10.1136/bmj.m4573 PMID: 33441402 PMCID: PMC7804890 Pawaskar M., Bilir S.P., Kowal S., Li Q., Weiss T., and Davies G., 2021, Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes, The American Journal of Managed Care, 27(8): e269-e277. https://doi.org/10.37765/ajmc.2021.88728 PMID: 34460181
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==